The world’s pharmaceutical industry continued its trend of consolidation Thursday as Sweden-based drug company Meda announced plans to acquire Italy’s Rottapharm for $3.1 billion.
Reports say the takeover marks the largest merger ever struck in Media’s history.
The pharmaceutical giant had earlier said that it prefers “to eat and not be eaten” in a global market that has seen a wave of M&A activity in recent months. According to reports, Meda has turned down a takeover offer by Mylan, based in the US.
Some industry experts had hoped Mylan would up its bid for the deal, but those hopes were dashed when Mylan acquired a portfolio from rival Abbott earlier last month.
Meda and Rottapharm expect to finalize the deal in the fourth quarter.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Approves 1.2 Billion Euros in Aid to Propel EU Cloud Computing
Dec 5, 2023 by
CPI
FTC Probe into Exxon’s Record-Breaking $60 Billion Pioneer Acquisition
Dec 5, 2023 by
CPI
Ericsson and AT&T Forge Historic $14 Billion Pact
Dec 5, 2023 by
CPI
Amazon Accuses Microsoft of Anticompetitive Practices in UK Cloud Market Probe
Dec 5, 2023 by
CPI
Binance Settlement: Turning Point for U.S. Crypto Enforcement, Sets Governance Template
Dec 5, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Horizontal Competition: Mergers, Innovation & New Guidelines
Nov 30, 2023 by
CPI
Innovation in Merger Control
Nov 30, 2023 by
CPI
Making Sense of EU Merger Control: The Need for Limiting Principles
Nov 30, 2023 by
CPI
Sustainability Agreements in the EU: New Paths to Competition Law Compliance
Nov 30, 2023 by
CPI
Merger Control and Sustainability: A New Dawn or Nothing New Under the Sun?
Nov 30, 2023 by
CPI